Cost-Effectiveness of Glatiramer Acetate and Interferon Beta-1a for Relapsing-Remitting Multiple Sclerosis, Based on the Combirx Study
Nov 1, 2013, 00:00 AM
10.1016/j.jval.2013.08.1827
https://www.valueinhealthjournal.com/article/S1098-3015(13)03732-7/fulltext
Section Title :
Disease-Specific Studies
Section Order :
1668
First Page :
A623
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(13)03732-7&doi=10.1016/j.jval.2013.08.1827